Brainsway Receives Health Canada Approval

Brainsway Receives Health Canada Approval

JERUSALEM, Jan. 16, 2013 (GLOBE NEWSWIRE) -- Brainsway Ltd. (TASE:BRIN)
("Brainsway" or the "Company") announced today that it has received a medical
device license to market its Deep TMS system in Canada for the treatment of
depression in patients for whom drug treatment has not improved their

According to the Canadian Psychiatric Association, one in four women and one
in ten men can expect to develop depression at some point in their lives.
People experiencing depression may have thoughts of suicide. In fact, many
doctors believe that depression is the illness that underlies the majority of
suicides in Canada. Suicide is one of the leading causes of death among people
between the ages of 15 to 24.

Uzi Sofer, CEO of Brainsway, commented, "On the heels of U.S. FDA approval of
our Deep TMS technology, this Health Canada approval represents the
achievement of another significant regulatory and commercialization milestone
for our Company.More importantly, Deep TMS offers hope, in many cases for the
first time, to those Canadians suffering from depression that have failed to
respond to drug therapy. Canada is an important market for us and we look
forward to making this groundbreaking treatment available there soon."

About Brainsway Ltd.

Brainsway develops a medical device for the noninvasive treatment of common
brain disorders. The device is based on a uniquely shaped electromagnetic coil
connected to a rapidly changing current supply, which produces magnetic fields
capable of affecting different areas of the brain. Deep brain areas can be
either excited or inhibited, depending on the frequency of the magnetic field.

CONTACT: Stephen Kilmer
         Tel: 212.618.6347
Press spacebar to pause and continue. Press esc to stop.